SCHEMBL4775267

SCHEMBL4775267

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
MAPT P10636 7/20 0.52
HPGD P15428 1/20 0.52
GAA P10253 2/20 0.49
LMNA P02545 4/20 0.45
KMT2A Q03164 3/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777409 0.85 ALDH1A1 (0.51) ALDH1A1MAPTGAALMNAKMT2A
SCHEMBL4772365 0.83 GAA (0.50) ALDH1A1MAPTHPGDGAALMNA
SCHEMBL4767920 0.83 NR1H4 (0.50) ALDH1A1MAPTHPGDGAALMNA
SCHEMBL4773148 0.83 ALDH1A1 (0.56) ALDH1A1HPGDGAALMNAKMT2A
SCHEMBL4767929 0.83 GAA (0.42) ALDH1A1MAPTGAALMNAKMT2A
SCHEMBL4776454 0.82 ALDH1A1 (0.46) ALDH1A1MAPTHPGDGAALMNA
SCHEMBL4775207 0.81 GAA (0.69) ALDH1A1MAPTHPGDGAALMNA
SCHEMBL4775349 0.80 LMNA (0.41) ALDH1A1MAPTHPGDGAALMNA
SCHEMBL4769594 0.80 GAA (0.48) ALDH1A1MAPTHPGDGAALMNA
SCHEMBL4773061 0.80 GAA (0.59) ALDH1A1HPGDGAALMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ALDH1A1 2159/4885MAPT 294/4885HPGD 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.